



CLAIMS

1. A compound that is selected from:




or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 that is:




or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 that is:




or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1 that is:




or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a compound that is selected from:




or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

6. A pharmaceutical composition according to claim 5 comprising the compound




or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition according to claim 5 comprising the compound




or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition according to claim 5 comprising the compound



or a pharmaceutically acceptable salt thereof.

9. A compound selected from:




pharmaceutically acceptable salt thereof, for use in the treatment of uveal melanoma.

10. The compound according to claim 2, or the pharmaceutically acceptable salt thereof, for use in the treatment of uveal melanoma.

11. The compound according to claim 3, or the pharmaceutically acceptable salt thereof, for use in the treatment of uveal melanoma.

12. The compound according to claim 4, or the pharmaceutically acceptable salt thereof, for use in the treatment of uveal melanoma.

13. Use of a compound selected from:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of uveal melanoma.

14. Use of the compound according to claim 2,

or the pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of uveal melanoma.

15. Use of the compound according to claim 3,

or the pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of uveal melanoma.

16. Use of the compound according to claim 4,

or the pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of uveal melanoma..

17. The use according to any one of claims 13-16, wherein the uveal melanoma is treated in a subject harboring GNAQ mutations.

18. The use according to any one of claims 13-16, wherein the uveal melanoma is treated in a subject harboring GNA11 mutations.

19. The use according to any one of claims 13-16, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination with at least one additional therapeutic agent.